AstraZeneca PLC (NASDAQ:AZN) Shares Bought by Coppell Advisory Solutions LLC

Coppell Advisory Solutions LLC lifted its stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 75.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 33,230 shares of the company's stock after acquiring an additional 14,339 shares during the quarter. Coppell Advisory Solutions LLC's holdings in AstraZeneca were worth $2,179,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of AZN. Nordea Investment Management AB purchased a new position in shares of AstraZeneca in the 4th quarter valued at about $754,000. Diversify Wealth Management LLC lifted its position in shares of AstraZeneca by 3.6% during the 4th quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company's stock worth $295,000 after buying an additional 153 shares during the last quarter. Ameritas Advisory Services LLC boosted its holdings in shares of AstraZeneca by 25.9% in the 4th quarter. Ameritas Advisory Services LLC now owns 9,487 shares of the company's stock valued at $622,000 after buying an additional 1,949 shares in the last quarter. Oak Ridge Investments LLC boosted its holdings in shares of AstraZeneca by 5.4% in the 4th quarter. Oak Ridge Investments LLC now owns 143,973 shares of the company's stock valued at $9,433,000 after buying an additional 7,341 shares in the last quarter. Finally, Asio Capital LLC grew its position in shares of AstraZeneca by 11.6% in the 4th quarter. Asio Capital LLC now owns 53,541 shares of the company's stock valued at $3,508,000 after buying an additional 5,569 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on AZN shares. BNP Paribas started coverage on AstraZeneca in a report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price objective on the stock. UBS Group upgraded AstraZeneca from a "neutral" rating to a "buy" rating in a research note on Thursday, February 13th. Finally, Morgan Stanley began coverage on shares of AstraZeneca in a report on Wednesday, February 12th. They issued an "overweight" rating on the stock. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, AstraZeneca currently has an average rating of "Buy" and an average price target of $88.00.

AstraZeneca Price Performance

AstraZeneca stock traded up $0.20 during midday trading on Monday, reaching $69.77. 4,497,639 shares of the company were exchanged, compared to its average volume of 5,173,364. The company has a market capitalization of $216.37 billion, a price-to-earnings ratio of 30.87, a P/E/G ratio of 1.42 and a beta of 0.49. AstraZeneca PLC has a 1 year low of $61.24 and a 1 year high of $87.68. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 0.93. The firm's 50-day simple moving average is $72.33 and its 200-day simple moving average is $70.16.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.05 EPS for the quarter, missing analysts' consensus estimates of $1.10 by ($0.05). AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. On average, analysts anticipate that AstraZeneca PLC will post 4.51 EPS for the current year.

AstraZeneca Increases Dividend

The company also recently announced a semi-annual dividend, which was paid on Monday, March 24th. Stockholders of record on Friday, February 21st were issued a dividend of $1.03 per share. The ex-dividend date of this dividend was Friday, February 21st. This represents a dividend yield of 2%. This is a boost from AstraZeneca's previous semi-annual dividend of $0.49. AstraZeneca's payout ratio is presently 91.15%.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.